ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.054 AUD -1.82% Market Closed
Market Cap: 109.2m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

Wall Street
Price Targets

IPD Price Targets Summary
ImpediMed Ltd

Wall Street analysts forecast IPD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPD is 0.156 AUD with a low forecast of 0.091 AUD and a high forecast of 0.21 AUD.

Lowest
Price Target
0.091 AUD
68% Upside
Average
Price Target
0.156 AUD
188% Upside
Highest
Price Target
0.21 AUD
289% Upside
ImpediMed Ltd Competitors:
Price Targets
ABT
Abbott Laboratories
12% Upside
ZBH
Zimmer Biomet Holdings Inc
16% Upside
RMD
Resmed Inc
0% Downside
SYK
Stryker Corp
6% Upside
NVST
Envista Holdings Corp
11% Downside
LIVN
LivaNova PLC
48% Upside
TFX
Teleflex Inc
29% Upside

Revenue
Forecast

Revenue Estimate
ImpediMed Ltd

For the last 8 years the compound annual growth rate for ImpediMed Ltd's revenue is 7%. The projected CAGR for the next 3 years is 66%.

7%
Past Growth
66%
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Operating Income
Forecast

Operating Income Estimate
ImpediMed Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
ImpediMed Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-69%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IPD's stock price target?
Price Target
0.156 AUD

According to Wall Street analysts, the average 1-year price target for IPD is 0.156 AUD with a low forecast of 0.091 AUD and a high forecast of 0.21 AUD.

What is ImpediMed Ltd's Revenue forecast?
Projected CAGR
66%

For the last 8 years the compound annual growth rate for ImpediMed Ltd's revenue is 7%. The projected CAGR for the next 3 years is 66%.

Back to Top